Literature DB >> 25403944

Pharmacologic therapies for malignant glioma: a guide for clinicians.

Riccardo Soffietti1, Luca Bertero, Lorenzo Pinessi, Roberta Rudà.   

Abstract

This review covers the medical options for malignant gliomas based on the results of recent clinical trials and updated information on molecular markers of prognostic and predictive value. In addition to alkylating agents, the antiangiogenic drug bevacizumab is increasingly used, particularly in cases of recurrence. Supportive care, including antiedema agents, antiepileptic drugs and anticoagulants, represent complementary treatment approaches of the utmost clinical importance.

Entities:  

Mesh：

Year:  2014        PMID： 25403944     DOI： 10.1007/s40263-014-0215-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  68 in total

1.  Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Authors:  Jaime Gállego Pérez-Larraya; François Ducray; Olivier Chinot; Isabelle Catry-Thomas; Luc Taillandier; Jean-Sébastien Guillamo; Chantal Campello; Annick Monjour; Stéphanie Cartalat-Carel; Maryline Barrie; Aymeri Huchet; Patrick Beauchesne; Mona Matta; Karima Mokhtari; Marie-Laure Tanguy; Jérôme Honnorat; Jean-Yves Delattre
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

2.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

3.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Authors:  Terri S Armstrong; Jeffrey S Wefel; Meihua Wang; Mark R Gilbert; Minhee Won; Andrew Bottomley; Tito R Mendoza; Corneel Coens; Maria Werner-Wasik; David G Brachman; Ali K Choucair; Minesh Mehta
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Authors:  A W Tolcher; S L Gerson; L Denis; C Geyer; L A Hammond; A Patnaik; A D Goetz; G Schwartz; T Edwards; L Reyderman; P Statkevich; D L Cutler; E K Rowinsky
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640
View more
  5 in total

1.  Long non-coding RNA Fer-1-like family member 4 is overexpressed in human glioblastoma and regulates the tumorigenicity of glioma cells.

Authors:  Feng Ding; Hongtu Tang; Dekang Nie; Liang Xia
Journal:  Oncol Lett       Date:  2017-06-16       Impact factor: 2.967

2.  Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression.

Authors:  Alexey Stupnikov; Paul G O'Reilly; Caitriona E McInerney; Aideen C Roddy; Philip D Dunne; Alan Gilmore; Hayley P Ellis; Tom Flannery; Estelle Healy; Stuart A McIntosh; Kienan Savage; Kathreena M Kurian; Frank Emmert-Streib; Kevin M Prise; Manuel Salto-Tellez; Darragh G McArt
Journal:  JCO Precis Oncol       Date:  2018-09-13

3.  FER1L4/miR-372/E2F1 works as a ceRNA system to regulate the proliferation and cell cycle of glioma cells.

Authors:  Liang Xia; Dekang Nie; Guangtao Wang; Caixing Sun; Gao Chen
Journal:  J Cell Mol Med       Date:  2019-03-19       Impact factor: 5.310

4.  Expression and prognostic significance of CTBP2 in human gliomas.

Authors:  Yong Wang; Shusheng Che; Gang Cai; Yuchao He; Jialei Chen; Wei Xu
Journal:  Oncol Lett       Date:  2016-08-11       Impact factor: 2.967

5.  Hepatoma-derived growth factor functions as an unfavorable prognostic marker of human gliomas.

Authors:  Yang Yang; Shengru Liang; Yuqian Li; Fei Gao; Longlong Zheng; Shilai Tian; Pu Yang; Lihong Li
Journal:  Oncol Lett       Date:  2017-10-13       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.